Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Eva Schaeffer, Andrea Pilotto, Daniela Berg
CNS Drugs (2014) Vol. 28, Iss. 12, pp. 1155-1184
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Historical Perspective: Models of Parkinson’s Disease
Shyh Jenn Chia, Eng‐King Tan, Yinxia Chao
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2464-2464
Open Access | Times Cited: 299
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Destany K. Kwon, Mohit Kwatra, Jing Wang, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3736-3736
Open Access | Times Cited: 78
Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
Wolfgang H. Oertel, Karla Eggert, Rajesh Pahwa, et al.
Movement Disorders (2017) Vol. 32, Iss. 12, pp. 1701-1709
Open Access | Times Cited: 152
Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson’s Disease?
Andrea Herrera Ronda, Patricia Muñoz, Harry W.M. Steinbusch, et al.
ACS Chemical Neuroscience (2017) Vol. 8, Iss. 4, pp. 702-711
Closed Access | Times Cited: 129
Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease
Maryka Quik, Danhui Zhang, Matthew McGregor, et al.
Biochemical Pharmacology (2015) Vol. 97, Iss. 4, pp. 399-407
Open Access | Times Cited: 109
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
Andrea de Bartolomeis, Licia Vellucci, Annarita Barone, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108236-108236
Open Access | Times Cited: 51
Parkinsonism and Related Disorders
Elizabeth Slow, Anthony E. Lang
DeckerMed Transitional Year Weekly Curriculum™ (2019)
Closed Access | Times Cited: 61
Clozapine: Why Is It So Uniquely Effective in the Treatment of a Range of Neuropsychiatric Disorders?
Dara Gammon, Catherine Cheng, Anna Volkovinskaia, et al.
Biomolecules (2021) Vol. 11, Iss. 7, pp. 1030-1030
Open Access | Times Cited: 51
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Ritam Bandopadhyay, Nainshi Mishra, Ruhi Rana, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 33
Nicotine and Nicotinic Receptor Drugs
Maryka Quik, Tanuja Bordia, Danhui Zhang, et al.
International review of neurobiology (2015), pp. 247-271
Closed Access | Times Cited: 63
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
Lawrence Elmer, Jorge L. Juncos, Carlos Singer, et al.
CNS Drugs (2018) Vol. 32, Iss. 4, pp. 387-398
Open Access | Times Cited: 51
Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson’s Disease
Yanqin Wang, Weilin Zhao, Ge Li, et al.
PPAR Research (2017) Vol. 2017, pp. 1-12
Open Access | Times Cited: 43
Continuous leg dyskinesia assessment in Parkinson's disease –clinical validity and ecological effect
Robert Ramsperger, Stefan Meckler, Tanja Heger, et al.
Parkinsonism & Related Disorders (2016) Vol. 26, pp. 41-46
Closed Access | Times Cited: 39
Does drug repurposing bridge the gaps in management of Parkinson’s disease? Unravelling the facts and fallacies
Bushra Bashir, Sukriti Vishwas, Gaurav Gupta, et al.
Ageing Research Reviews (2025) Vol. 105, pp. 102693-102693
Closed Access
Biological bases for a possible effect of cannabidiol in Parkinson’s disease
Nilson C. Ferreira‐Junior, Alline C. Campos, Francisco Silveira Guimarães, et al.
Brazilian Journal of Psychiatry (2019) Vol. 42, Iss. 2, pp. 218-224
Open Access | Times Cited: 33
Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials
Rajesh Pahwa, Stuart Isaacson, Joohi Jimenez‐Shahed, et al.
Parkinsonism & Related Disorders (2018) Vol. 60, pp. 118-125
Open Access | Times Cited: 29
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
Fabio Del Bello, Mario Giannella, Gianfabio Giorgioni, et al.
Biomolecules (2019) Vol. 9, Iss. 4, pp. 142-142
Open Access | Times Cited: 29
Drug reprofiling history and potential therapies against Parkinson’s disease
Komal Latif, Aman Ullah, Anastasiia D. Shkodina, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 14
Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARγ regulation
Hwei‐Hsien Chen, Pei-Chi Chang, Shiaw‐Pyng Wey, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 108, pp. 254-262
Open Access | Times Cited: 26
Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson’s Disease
Xiomara A. Perez
Neuropsychology Review (2015) Vol. 25, Iss. 4, pp. 371-383
Closed Access | Times Cited: 23
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease
Xi Chen, Yuanyuan Wang, Haifeng Wu, et al.
Neurological Sciences (2020) Vol. 41, Iss. 8, pp. 2055-2065
Closed Access | Times Cited: 20
Poor nighttime sleep is positively associated with dyskinesia in Parkinson's disease patients
Cheng‐Jie Mao, Yaping Yang, Juping Chen, et al.
Parkinsonism & Related Disorders (2017) Vol. 48, pp. 68-73
Open Access | Times Cited: 21
mGlu5, Dopamine D2and Adenosine A2AReceptors in L-DOPA-induced Dyskinesias
Nicolas Morin, Marc Morissette, Laurent Grégoire, et al.
Current Neuropharmacology (2016) Vol. 14, Iss. 5, pp. 481-493
Open Access | Times Cited: 19
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress
Sufang Zhang, Chenglong Xie, Jingya Lin, et al.
Molecular Medicine Reports (2017)
Open Access | Times Cited: 19
Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease
Julia Paik, Susan J. Keam
CNS Drugs (2018) Vol. 32, Iss. 8, pp. 797-806
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top